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Abstract
Background. Parkinson’s disease (PD) is a progressive neurodegenerative disease that causes severe brain
dopamine depletion. Disruption of iron metabolism may be involved in the PD progression. Objective. To test
the protective effect of (−)-epigallocatechin-3-gallate (EGCG) against 6-hydroxydopamine- (6-OHDA-)
induced neurotoxicity by regulating iron metabolism in N27 cells. Methods. Protection by EGCG in N27 cells
was assessed by SYTOX green assay, MTT, and caspase-3 activity. Iron regulatory gene and protein expression
were measured by RT-PCR and Western blotting. Intracellular iron uptake was measured using 55Fe. The
EGCG protection was further tested in primary mesencephalic dopaminergic neurons by
immunocytochemistry. Results. EGCG protected against 6-OHDA-induced cell toxicity. 6-OHDA treatment
significantly () increased divalent metal transporter-1 (DMT1) and hepcidin and decreased ferroportin 1
(Fpn1) level, whereas pretreatment with EGCG counteracted the effects. The increased 55Fe (by 96%, ) cell
uptake confirmed the iron burden by 6-OHDA and was reduced by EGCG by 27% (), supporting the DMT1
results. Pretreatment with EGCG and 6-OHDA significantly increased () TH+ cell count (~3-fold) and
neurite length (~12-fold) compared to 6-OHDA alone in primary mesencephalic neurons. Conclusions.
Pretreatment with EGCG protected against 6-OHDA-induced neurotoxicity by regulating genes and proteins
involved in brain iron homeostasis, especially modulating hepcidin levels.
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Background. Parkinson’s disease (PD) is a progressive neurodegenerative disease that causes severe brain dopamine depletion.
Disruption of iron metabolism may be involved in the PD progression. Objective. To test the protective effect of (−)-
epigallocatechin-3-gallate (EGCG) against 6-hydroxydopamine- (6-OHDA-) induced neurotoxicity by regulating ironmetabolism
in N27 cells. Methods. Protection by EGCG in N27 cells was assessed by SYTOX green assay, MTT, and caspase-3 activity. Iron
regulatory gene and protein expression were measured by RT-PCR and Western blotting. Intracellular iron uptake was measured
using 55Fe. The EGCG protection was further tested in primary mesencephalic dopaminergic neurons by immunocytochemistry.
Results. EGCG protected against 6-OHDA-induced cell toxicity. 6-OHDA treatment significantly (𝑝 < 0.05) increased divalent
metal transporter-1 (DMT1) and hepcidin and decreased ferroportin 1 (Fpn1) level, whereas pretreatment with EGCG counteracted
the effects. The increased 55Fe (by 96%, 𝑝 < 0.01) cell uptake confirmed the iron burden by 6-OHDA and was reduced by EGCG
by 27% (𝑝 < 0.05), supporting the DMT1 results. Pretreatment with EGCG and 6-OHDA significantly increased (𝑝 < 0.0001) TH+
cell count (∼3-fold) and neurite length (∼12-fold) compared to 6-OHDA alone in primary mesencephalic neurons. Conclusions.
Pretreatment with EGCG protected against 6-OHDA-induced neurotoxicity by regulating genes and proteins involved in brain
iron homeostasis, especially modulating hepcidin levels.
1. Introduction
Iron plays a crucial role in many physiological functions
including DNA synthesis, oxygen transport, and mitochon-
drial respiration [1–3]. Iron also serves as a cofactor of many
enzymes, such as tyrosine hydroxylase, which is involved in
brain function. It is important to regulate intracellular iron
uptake, transport, and storage to maintain iron homeostasis
because both low and high iron levels can be detrimental
to brain function. The accumulation of non-protein-bound
iron in the cell can induce oxidative damage to cellular
organelles by producing free radicals via the Fenton reaction
[4], resulting in chronic neurological disorders, including
Parkinson’s disease (PD) [5, 6].
Divalent metal transporter-1 (DMT1) is one of the
proteins responsible for cell iron uptake. DMT1 can be
upregulated by neurotoxins, such as 6-hydroxydopamine (6-
OHDA), resulting in excess iron influx and neurodegenera-
tion [7–9]. However, it is still unclear whether iron influx and
subsequent free radical formation is a primary or a secondary
event in the neurodegenerative process of PD. Hepcidin is
expressed in several organs, such as the liver, brain, and
spinal cord, and is a key iron regulatory protein responsible
for normal iron homeostasis. Hepcidin can bind to iron
exporter ferroportin 1 (Fpn1), causing its internalization and
degradation, thereby promoting iron retention in the cell
[10]. Hepcidin expression is influenced by intracellular iron
concentration and oxidative stress [11]. Because 6-OHDA has
been shown to alter DMT1 expression and induce oxidative
stress [7], it is possible that 6-OHDA may exert its neuro-
toxicity by interrupting iron homeostasis through hepcidin
and, consequently, may cause more oxidative damage. It has
been shown that 6-OHDA also can release iron from ferritin,
which can induce oxidative stress, causing neuronal cell death
[12, 13]. However, the detailed mechanisms remain unclear.
Green tea polyphenols have been shown to provide
beneficial effects against cancer, inflammation, and neuro-
logical disorders. (−)-Epigallocatechin-3-gallate (EGCG) is
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the most abundant polyphenol in green tea and has been
shown to protect against neurotoxicity in several cell culture
models due to its capability of scavenging free radicals
and chelating iron [14, 15]. Several in vitro studies have
shown that EGCG reduces 6-OHDA neurotoxicity, but the
mechanism of the protection is not clear. We hypothesized
that 6-OHDA disrupts brain iron metabolism by altering
iron-related proteins and that EGCG administration would
normalize these adverse effects. We used immortalized rat
mesencephalic dopaminergic neuronal cell line (N27 cells)
as well as primary mesencephalic dopaminergic neurons to
determine the neuroprotective effect of EGCG against 6-
OHDA. We also determined whether EGCG protection of
normalizing the disruption of iron metabolism induced by
6-OHDA is by regulation of DMT1, Fpn1, and hepcidin.
2. Material and Methods
2.1. Reagents. EGCG, 6-OHDA, and thiazolyl blue tetra-
zolium bromide (MTT) were purchased from Sigma-
Aldrich (St. Louis, MO), and SYTOX Green Nucleic Acid
Stain was purchased from Molecular Probes (Eugene, OR).
Substrate for caspase-3, acetyl-Asp-Glu-Val-Asp-AFC (Ac-
DEVD-AFC), was obtained from MP Biomedicals (Solon,
OH). The mouse TH+ antibody was obtained from Mil-
lipore (Temecula, CA); Alexa 680-conjugated anti-mouse
secondary antibodies, RPMI-1640 medium, fetal bovine
serum, L-glutamine, penicillin, streptomycin and neurobasal
medium, B27 supplement, and Dulbecco’s modified Eagle’s
medium (DMEM) were obtained from Invitrogen (Carlsbad,
CA). Rabbit anti-rat DMT1 polyclonal antibody (Catalog:
NRAMP21A), rabbit anti-rat MTP1 polyclonal antibody
(Catalog: MTP11-A), and rabbit anti-rat hepcidin polyclonal
antibody (Catalog: HEPC-11A) were purchased from Alpha
Diagnostic International (San Antonio, TX), and 𝛽-actin
mouse anti-mousemonoclonal antibodywas purchased from
Sigma-Aldrich (St. Louis, MO). Secondary goat anti-rabbit
IgG-HRP (Catalog: sc-2004) and goat anti-mouse IgG-HRP
(Catalog: sc-2005) were obtained from Santa Cruz Biotech-
nology (Dallas, TX). SuperSignal West Femto chemilumi-
nescent substrate for Western blotting was obtained from
Thermo Scientific (Rockford, IL). 55Fe was purchased from
PerkinElmer (Waltham, MA). Scintanalyzed ScintiVerse BD
Cocktail was purchased from Fisher Scientific (Pittsburgh,
PA).
2.2. Cell Culture. N27 cells were kindly gifted byDr. Kedar N.
Prasad (University of ColoradoHealth Sciences Center, Den-
ver, CO) and were grown in RPMI-1640 medium containing
10% fetal bovine serum, 2mM L-glutamine, 50U penicillin,
and 50 𝜇g/mL streptomycin and maintained at 37∘C in a
humidified atmosphere containing 5% CO
2
as described in
previous studies [16].
We also used primary mesencephalic dopaminergic neu-
ronal cultures to determine the neuroprotective effect of
EGCG on TH+ cells. All of the procedures involving animal
handling were approved by the Institutional Animal Care
Use Committee (IACUC) at Iowa State University. Primary
cultures were prepared from the ventral mesencephalon of
gestational 14-day-old C57 black mice embryos as described
previously [17]. Mesencephalic tissues were dissected and
kept in ice-cold Ca2+-free Hanks’ balanced salt solution.
Cells then were dissociated in Hanks’ balanced salt solution
containing trypsin 0.25% EDTA for 30min at 37∘C. Cells
were suspended in neurobasal medium with 2% neurobasal
supplement (B27) after 10% FBS inactivating enzyme activity
in DMEM medium. The cells were then plated at a density
of 0.5 × 106 cells on 12mm coverslips precoated with
1mg/mL poly-D-lysine. Cell cultures were maintained in
500𝜇M of L-glutamine, 100 IU/mL of penicillin, and 100
units of streptomycin neurobasal medium and incubated in a
humidifiedCO
2
incubator (5%CO
2
and 37∘C).Half of the cell
media were replaced every 2 days, and assays were conducted
using cultures at 7 days. Primary cultures were exposed to 6-
OHDA (25 𝜇M) for 24 h in the presence or absence of 2 h of
pretreatmentwith EGCG (1, 10, and 100 𝜇M, resp.). Cells were
then fixed for immunocytochemical analysis.
2.3. SYTOX Green Assay. N27 cells grown in 24-well plates
with 500 𝜇L of RPMI-1640 medium were coincubated with
1 : 1000 SYTOX green dye. To determine the dose-response
protective effect of EGCG from 6-OHDA damage, N27 cells
were pretreated with EGCG at concentrations of 1, 10, 50, and
100 𝜇M for 2 h, followed by 6-OHDA (100𝜇M) treatment for
6 h.The assessment of cell deathwas conducted using SYTOX
green nucleic stain as described previously [17]. After each
treatment, SYTOX green fluorescence signal was detected
using a microplate reader (Bio-Tek microplate reader, VT)
at an excitation wavelength of 485 nm and an emission
wavelength of 538 nm. The intensity of fluorescence was
directly proportional to the number of dead cells, which
was monitored by Nikon inverted fluorescence microscope
equipment (Model TE-2000U, Diagnostic Instruments, Ster-
ling Heights, MI).
2.4. Cell Viability. The N27 cells were pretreated and
cotreated with 100𝜇M of EGCG followed by 6-OHDA treat-
ment for 6 h, and the cell viability was measured using MTT
assay as described previously [18]. Briefly, cells were washed
with PBS after treatments and then incubated with serum-
free RPMI medium containing 0.25mg/mL of MTT reagent
for 3 h at 37∘C. Isopropanol-HCl (0.04M) solutionwas added
to dissolve intracellular purple formazan, and absorbancewas
read at 570 nm with a reference wavelength of 630 nm using
a microplate reader (Molecular Devices, Sunnyvale, CA) to
assess cell viability.
2.5. Caspase-3 Activity. Caspase-3 activity was measured to
assess cell apoptosis as previously described [19]. Briefly,
N27 cells were pretreated with 100 𝜇M of EGCG for 2 h
followed by 100𝜇M 6-OHDA treatment for 6 h. Then, the
cells were suspended in lysis buffer (50mM of Tris-HCl,
1mM of EDTA, and 10M of EGTA) containing 10mM of
digitonin for 20min at 37∘C. Supernatants were treated with
the fluorogenic substrate Ac-DEVD-AFC for 1 h at 37∘C,
and fluorescence was measured at excitation at 400 nm and
emission at 505 nm using a microplate reader. The activity
was measured as fluorescent units per mg protein.
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2.6. Immunocytochemistry. The primary mesencephalic
dopaminergic neurons were used for analysis of TH+ cells
by using an immunocytochemistry method [16]. Cells
were fixed with 4% paraformaldehyde and permeabilized.
Nonspecific sites were blocked with 5% normal goat serum
containing 0.4% BSA and 0.2% Triton-X 100 in PBS for
20min. Cells were then incubated with antibodies directed
against TH+ (1 : 500) overnight at 4∘C followed by incubation
with Cy3-conjugated (1 : 1000) secondary antibody for 1 h
at room temperature. Secondary antibody treatments were
followed by incubation with 10 𝜇g/mL of Hoechst 33342
for 3min at room temperature to stain the nucleus. Then,
the coverslips containing cells were washed with PBS,
mounted on a slide, and viewed under a Nikon inverted
fluorescence microscope; images were captured with a SPOT
digital camera (Diagnostic Instruments, Sterling Heights,
MI). TH+ cell count and neurite processes were measured
as described previously [16]. For measurement of TH+
cell count, MetaMorph image analysis software was used.
Neuronal count and volume were measured on the threshold
images using Integrated Morphometry Analysis (IMA).
Neuronal process lengths were marked by applying the
region and length measurement function in the IMA [20].
2.7. Quantitative Real-Time PCR Analyses. The mRNA levels
of DMT1, Fpn1, hepcidin, transferrin receptor (TfR), and
H-ferritin were quantified using real-time PCR for gene
expression analysis as described previously [21, 22]. N27
cells were pretreated with 100 𝜇M of EGCG followed by
25 𝜇M of 6-OHDA for 24 h. We used low concentration of
6-OHDA in these experiments to prevent severe cell death
so that we would be able to detect the expression of iron-
related proteins. Total RNA was isolated from the cells using
Absolutely RNAMiniprep Kits (Stratagene, Santa Clara, CA)
and reverse transcribed by High Capacity cDNA Reverse
TranscriptionKits (Applied Biosystems, Foster City, CA). RT-
PCR was performed using the Brilliant SYBR Green QPCR
Master Mix Kit and the Mx3000P QPCR System (Stratagene,
Santa Clara, CA). The 25𝜇L PCR reaction mixtures included
1 𝜇L of cDNA (produced by 100 ng of RNA), 12.5 𝜇L of
2x master mix, and 100 nM of each primer (synthesized
by Integrated DNA Technologies, Coralville, IA, listed in
Table 1). Cycling conditions contained an initial denaturation
at 95∘C for 10min followed by 40 cycles of amplification at
95∘C for 30 s for denaturation, 60∘C for 30 s for annealing, and
72∘C for 30 s for extension. Fluorescence was detected during
the annealing/extension step of each cycle.TheGAPDH gene
was used as an internal control. A comparative threshold
cycle method was used to analyze the data. All reactions were
performed in triplicate. Results were compared to the control
without any treatment.
2.8. Western Blot Analyses. DMT1, hepcidin, and Fpn1 pro-
tein expressions were evaluated by Western blot assay. N27
cells were pretreated with 100 𝜇M of EGCG followed by
25 𝜇M of 6-OHDA for 24 h. Then, the cells were washed
with cold PBS, homogenized in RIPA buffer containing 1%
Triton X-100, 0.1% SDS, 1mM of phenylmethanesulfonyl
fluoride (PMSF), and protease inhibitors (1mg/mL each of
Table 1: Effect of 6-OHDA and EGCG on the iron-related gene
expression (mean ± SEM, 𝑛 = 3–6).
6-OHDA EGCG + 6-OHDA p
DMT1 + IRE 2.3 ± 0.2∗ 0.9 ± 0.0ns <0.001
Hepcidin 1.7 ± 0.1∗ 0.8 ± 0.2ns <0.01
Fpn1 0.7 ± 0.0∗ 1.2 ± 0.2ns <0.05
H-ferritin 2.4 ± 0.4∗ 1.1 ± 0.2ns <0.05
TfR1 0.7 ± 0.0∗ 1.3 ± 0.1ns <0.01
TfR2 1.5 ± 0.1∗ 1.1 ± 0.1ns <0.05
N27 cells were treated with 25𝜇M of 6-OHDA for 24 h following pretreat-
ment by EGCG 100 𝜇M for 2 h.The values are ratios compared to the control
after individual mRNA values were normalized to GAPDH expression. p
values indicate the difference between the 6-OHDA and the EGCG + 6-
OHDA treatment groups.
∗
𝑝 < 0.05; ns: not significant compared to control.
Differences were determined using Student’s 𝑡-test.
pepstatin, aprotinin, and leupeptin), and then sonicated on
ice. The supernatant was collected after centrifugation at
10,000 g for 15min at 4∘C, and protein concentration was
determined. Forty micrograms of protein extract was mixed
with an equal volume of 5x sample buffer (0.35M Tris-
HCl, 10% SDS, 30% glycerol, and 0.012% bromophenol blue)
and loaded onto a 12% SDS-polyacrylamide gel or 15% urea
gel, electrophoresed, and then transferred to a nitrocellulose
membrane (Bio-Rad, Hercules, CA). The membrane was
blockedwith 5% nonfat drymilk in TBSwith Tween and then
incubated with rabbit anti-rat DMT1 with IRE polyclonal
antibody (1 : 200), rabbit anti-rat Fpn1 polyclonal antibody
(1 : 500), or rabbit anti-rat hepcidin polyclonal antibody
(1 : 500), followed by horseradish peroxidase-conjugated goat
anti-rat IgG antibody (1 : 3000). 𝛽-actin (1 : 2000) was used
to normalize protein loading. All Western blot assays were
performed in triplicate in two separate experiments, and the
band densities were compared to the control without any
treatment.
2.9. Cellular Iron Uptake. N27 cells were grown in 12-well
plates and exposed to 25 𝜇M of 6-OHDA after 2 h pretreat-
ment with 100 𝜇M of EGCG. Ferric chloride (0.5 𝜇Ci/mL
55Fe) was added to the cell medium and incubated at 37∘C
for 24 h. Cells were then washed twice with cold 1x PBS,
lysed in 250 𝜇L of RIPA buffer, and centrifuged at 10,000 g
for 10min at 4∘C. The 55Fe radioactivity in the supernatant
was measured in a scintillation counter premixed with 10mL
scintillation cocktail. Cell uptake was measured based on the
fraction of radioactivity found in the cell lysate in relation to
the initially added amount.The experiments were performed
in duplicate, and the 55Fe uptake was represented as counts
per minute normalized to cell protein concentration.
2.10. Statistical Analyses. Data were analyzed with Prism 4.0
software (Graph Software, San Diego, CA). All values are
expressed as themean± SEMand represented as a percentage
of the respective controls. ANOVA with Tukey’s multiple
comparison tests was used to detect the differences among
the treatments. Student’s 𝑡-test was used to compare the
differences in iron-related gene expression between 6-OHDA
4 Parkinson’s Disease
C
ell
 d
ea
th
 (%
 o
f c
on
tro
l)
∗
∗
A
B B B
C
A
EGCG (𝜇M)
6-OHDA
− 0 1 10 50 100
− + + + + +
0
100
200
300
400
(a)
C
el
l v
ia
bi
lit
y 
(%
 o
f c
on
tro
l)
C
on
tro
l
6
-O
H
D
A
Pr
e-
tr
t+
6
-O
H
D
A
C
o-
tr
t+
6
-O
H
D
A
A
B
C
B
0
50
100
150
(b)
Ca
sp
as
e-
3
ac
tiv
ity
 (%
 o
f c
on
tro
l)
C
on
tro
l
6-
O
H
D
A
EG
CG
+
6-
O
H
D
A
A
B
C
0
500
1000
1500
(c)
Figure 1: Effect of 6-OHDAand EGCGonN27 cell death, cell viability, and cell apoptosis. Data are represented as% of control (no treatment).
Cell death (a) was determined by SYTOX green assay, and values aremean ± SEM, 𝑛 = 8. Cells were pretreated with EGCG for 2 h followed by
100𝜇M6-OHDA treatment for 6 h. Bars without common letters differ. Cell viability (b) was evaluated byMTT assay. 6-OHDA, 100𝜇moles/L
for 6 h; EGCG, 100𝜇moles/L. Pre-trt EGCG: pretreatment for 2 h; Co-trt EGCG: cotreatment with 6-OHDA. Values are mean ± SEM, 𝑛 = 6.
Cell apoptosis (c) was measured as caspase-3 activity. 6-OHDA (100 𝜇M) for 6 h following EGCG (100 𝜇M) pretreatment for 2 h. Values are
mean ± SEM, 𝑛 = 3. Labeled bars without a common letter differ. ∗𝑝 < 0.001.
with EGCG pretreatment and 6-OHDA treatment alone
groups. The mean differences were considered significant at
𝑝 ≤ 0.05.
3. Results
3.1. Effects of 6-OHDA and EGCG on Cell Death. Based on
the SYTOX green assay, EGCG protected against 6-OHD-
induced cell death in a dose-response manner (Figure 1(a)).
6-OHDA significantly increased cell death by ∼3-fold (𝑝 <
0.0001) compared to the control. Pretreatment with EGCG at
a concentration of 50 and 100 𝜇M for 2 h decreased cell death
by 31% (𝑝 < 0.0001) and 55% (𝑝 < 0.0001), respectively. Cell
death with 100 𝜇M EGCG pretreatment was not significantly
different from the control but was significantly lower than for
the 6-OHDA alone. No protection for cell death was found at
low concentrations of EGCG (1 and 10 𝜇M).
3.2. EGCG Protected against 6-OHDA-Induced Decreased
Cell Viability. As shown in Figure 1(b), cell viability was
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decreased to 59% (𝑝 < 0.001) after 6 h of treatment
with 6-OHDA, but EGCG pretreatment for 2 h significantly
protected against this toxicity by 21% (𝑝 < 0.01). In contrast,
no protection for cell viability was found with the EGCG
cotreatment group, suggesting that EGCG does not provide
a neurorescue effect.
3.3. EGCG Protected against 6-OHDA-Induced Cell Apop-
tosis. Cell apoptosis, as measured by caspase-3 activity
(Figure 1(c)), was determined only with pretreatment, not
cotreatment, of ECCG as it did not show a neurorescue
effect in the cell viability experiments. Compared to control,
6-OHDA significantly increased caspase-3 activity by ∼12-
fold (𝑝 < 0.0001), whereas pretreatment with EGCG for
2 h decreased the caspase-3 activity by 49% (𝑝 < 0.0001)
compared to 6-OHDA treatment.
3.4. EGCG Decreased TH+ Neuronal Loss from 6-OHDA in
Primary Cultures. Treatment with 6-OHDA for 24 h induced
∼80% (𝑝 < 0.0001) loss of TH+ cell count (Figure 2(e)),
compared to the control. Pretreatment with EGCG (1, 10, and
100 𝜇M) for 2 h significantly increasedTH+ cell count by 155%
(𝑝 < 0.01), 205% (𝑝 < 0.001), and 290% (𝑝 < 0.0001), respec-
tively (Figure 2(e)). EGCG at 100 𝜇M concentration com-
pletely protectedTH+ cell loss, as shownby the nonsignificant
difference when compared to the control.The average lengths
of TH+ neuronal processes in EGCG-pretreated cells were
significantly longer than those treated with only 6-OHDA.
We found that 6-OHDA significantly decreased the TH+
neurite length by 93% (𝑝 < 0.0001), whereas pretreatment
with EGCG (1, 10, and 100𝜇M) for 2 h significantly increased
the neurite length by ∼10-fold (𝑝 < 0.0001), 12-fold (𝑝 <
0.0001), and 12-fold (𝑝 < 0.0001), respectively (Figure 2(f)).
In addition, Hoechst staining was used to verify the cell
viability. 6-OHDA significantly decreased Hoechst activity,
whereas pretreatmentwith EGCG (1, 10, or 100𝜇M) increased
Hoechst staining (data not shown), suggesting that the
cell viability in the primary culture increased with EGCG.
Overall, the protection of EGCG against 6-OHDA toxicity
was shown to be effective, even in the primary cultures.
3.5. EGCG Altered the Effect of 6-OHDA on the mRNA
Expression of Iron-Related Genes. As shown in Table 2, 6-
OHDA at 25 𝜇M for 24 h significantly increased the mRNA
expression of DMT1 + IRE, hepcidin, TfR2, and H-ferritin
and decreased the mRNA expression of Fpn1 and TfR1.
However, EGCG counteracted the effect by decreasing the
mRNA expression of DMT1 + IRE by 60% (𝑝 < 0.001),
hepcidin by 54% (𝑝 < 0.05), H-ferritin by 53% (𝑝 < 0.05),
and TfR2 by 27% (𝑝 < 0.05) while increasing the mRNA
expression of Fpn1 by 70% (𝑝 < 0.01) and TfR1 by 96% (𝑝 <
0.05), compared to treatment with only 6-OHDA, suggesting
the reduced iron burden in the cell.
3.6. EGCG Altered the 6-OHDA Effect on Iron-Related Protein
Expressions. Similar to the gene expression results, 6-OHDA
significantly increased protein expression of DMT1 + IRE by
2-fold (𝑝 < 0.05) and hepcidin by 77% (𝑝 < 0.05) and
decreased expression of Fpn1 by 61% (𝑝 < 0.0001) compared
Table 2: Summary of the primers for iron-related gene expression.
Hepcidin
Forward GAA GGC AAG ATG GCA CTA AGC A
Hepcidin
Reverse TCT CGT CTG TTG CCG GAG ATA G
Fpn1 Forward CCA CCT GTG CCT CCC AGA T
Fpn1 Reverse CCC ATG CCA GCC AAA AAT AC
DMT1 + IRE
Forward CAG TGC TCT GTA CGT AAC CTG TAA GC
DMT1 + IRE
Reverse CGC AGA AGA ACG AGG ACC AA
H-ferritin
Forward GCC CTG AAG AAC TTT GCC AAA T
H-ferritin
Reverse TGC AGG AAG ATT CGT CCA CCT
TfR1 Forward CTA GTA TCT TGA GGT GGG AGG AAG AG
TfR1 Reverse GAG AAT CCC AGT GAG GGT CAG A
TFR2
Forward AGC TGG GAC GGA GGT GAC TT
TFR2 Reverse TCC AGG CTC ACA TAC ACG ACA G
GAPDH
Forward CCT GGA GAA ACC TGC CAA GTA T
GAPDH
Reverse AGC CCA GGA TGC CCT TTA GT
All the primers were synthesized by Integrated DNA Technologies.
to the control. Pretreatment with EGCG normalized these
effects by decreasing DMT1 + IRE by 66% (𝑝 < 0.01) and
hepcidin by 43% (𝑝 < 0.05) and increasing Fpn1 by 82% (𝑝 <
0.01) compared to treatment with 6-OHDA alone (Figure 3).
3.7. EGCG Reduced Iron Burden Induced by 6-OHDA. As
shown in Figure 4, 6-OHDA significantly increased 55Fe
uptake by 96% (𝑝 < 0.01). Pretreatment with EGCG
significantly decreased cellular 55Fe by 27% (𝑝 < 0.05)
compared to treatment with 6-OHDA alone, supporting the
results of mRNA and protein expression.
4. Discussion
Neurotoxins, such as 6-OHDA, have been widely used to
study PD in in vitro and in vivo studies [7, 23, 24] because of
their ability to induce oxidative stress and cause mitochon-
drial dysfunction. High doses of 6-OHDA are commonly
used for studying short-term and acute pathological damage.
A previous study showed that 100 𝜇M of 6-OHDA for 6 h
caused complete loss of cells [25], but in our study, at the
same concentration, 6-OHDA decreased cell viability by
only ∼40% and increased N27 cell death by ∼3-fold and
cell apoptosis by ∼12-fold. We used a relatively lower dose
of 6-OHDA (25 𝜇M) to determine its regulatory effect on
iron-related mRNA and protein expression as well as on
intracellular iron uptake, given that a lower dose of 6-
OHDA favors better understanding of the mechanisms of
neurodegeneration before the complete loss of cells [26]. For
the primary cell cultures, lower concentrations of 6-OHDA
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Figure 2: Prevention of TH+ neuronal loss by EGCG induced by 6-OHDA in primary cultures. Cells were pretreated with EGCG (1, 10, and
100𝜇M) for 2 h followed by 6-OHDA (10𝜇M) for 24 h. Immunocytochemistry was used to measure the TH+ cells (arrow, (a), (b), (c), and
(d)). Quantification data on TH+ number (e) and neurite length (f). Values are mean ± SEM, 𝑛 = 3. Bars without common letters differ.
∗
𝑝
< 0.01; ∗∗𝑝 < 0.0001.
(<50𝜇M) were mostly used due to the high sensitivity of
primary neurons [27, 28], because a higher concentration of
6-OHDA (200𝜇M) showed complete death in rat primary
nigral culture [29]. In this study, we used 10 𝜇M of 6-
OHDA to show the significant TH+ cell loss after 24 h of
treatment. Overall, the dose of 6-OHDA used in different
studies depends on the cell type and the purpose of the study.
Several pathways, such as mitochondrial dysfunction,
oxidative stress, and inflammation, have already been pro-
posed to explain 6-OHDA-induced neurotoxicity. It also has
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Figure 3: Western blot analysis of the effect of 6-OHDA and EGCG on iron-related protein expression in N27 cells, DMT1 (+IRE) (a),
hepcidin (b), and Fpn1 (c), which were normalized by 𝛽-actin. Cells were treated with EGCG (100𝜇M) for 2 h prior to treatment with 6-
OHDA (25 𝜇M) for 24 h. Quantitative data for band intensity are shown in bottom panels, (d), (e), and (f), respectively. Values are mean ±
SEM, 𝑛 = 3. Bars without a common letter differ. ∗𝑝 < 0.05; ∗∗𝑝 < 0.01.
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Figure 4: 55Fe iron uptake by the N27 cell. Cells were treated with EGCG (100 𝜇M) for 2 h followed by 6-OHDA (25 𝜇M) for 24 h. Percentage
of 55Fe uptake was calculated by measuring the fraction of radioactivity in the cell lysates in relation to initial added radioactivity. Values
(mean ± SEM, 𝑛 = 3) are expressed as percentage of controls after normalizing with protein concentration. Bar means without a common
letter differ. ∗𝑝 < 0.05; ∗∗𝑝 < 0.01.
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been reported that 6-OHDA can release iron from ferritin
and alter DMT1 expression, suggesting it might exert its
toxicity by interrupting iron homeostasis by increasing intra-
cellular iron concentration and, in turn, inducing oxidative
stress [30, 31]. In our study, we also found that 6-OHDA
altered iron metabolism by altering iron regulatory gene
and protein expression. We showed that 6-OHDA increased
DMT1 + IRE and hepcidin expression and decreased Fpn1
expression, suggesting high cellular iron uptake and low iron
release causing cellular iron burden. The increase in ferritin
and transferrin receptor 2 (TfR2) with 6-OHDA treatment
supports the hypothesis of increased cellular iron concen-
trations. The radioactive iron uptake data also supports the
DMT1 results by showing increased iron uptake with 6-
OHDA.
Our results support previous studies that showed the
upregulation of DMT1 by 6-OHDA in an IRE/IRP-dependent
manner, indicating that 6-OHDA may affect the activity of
IRPs and increase the translation and stabilization of DMT1
mRNA [32, 33]. Because we found that 6-OHDA did not
alter the expression of DMT1 without IRE (data not shown),
we can speculate that DMT1 regulation by 6-OHDA may be
through IRP.The increase of DMT1might have caused higher
iron influx, leading to high oxidative stress.
Hepcidin, a key iron regulator, is mainly involved in
regulating iron homeostasis and can be upregulated by
increased iron influx and high oxidative stress [34, 35]. TfR2
has been shown to be positively correlated with hepcidin
expression [36, 37], and our results showing increased TfR2
and hepcidin expression support that relationship. Hepcidin
can bind to Fpn1 and induce its internalization and degra-
dation, decreasing iron export. In our study, we showed that
6-OHDA significantly increased hepcidin and suppressed
Fpn1 expression, which may result in higher intracellular
iron retention. Although we do not have data to show a
decrease in iron release to support the Fpn1 results, we can
postulate about that mechanism based on the upregulation
of hepcidin. Mixed results have been reported on the effect of
neurotoxins on Fpn1. Decreased Fpn1 and increased excess
iron were reported in an earlier study [38, 39]. On the
contrary, neurotoxins also were reported to upregulate Fpn1
expression in astrocytes and SH-SY5Y cells [39, 40]. The
difference in Fpn1 regulation may depend on cell type and
the nature of the neurotoxins.
Given that alteration of iron level in the brain has
been linked to several neurological disorders, maintaining
normal iron homeostasis seems to be an ideal strategy for
neuroprotection [41]. As an iron chelator and antioxidant,
EGCG has been reported in numerous studies to protect
against neurotoxicity [42–44]. In this study, EGCG pro-
tected N27 cells against 6-OHDA-induced cell death. The
EGCG pretreatment method was shown to be more effective
than cotreatment, suggesting that it offers neuroprotection
rather than a neurorescue effect. Although EGCG at lower
concentrations (10–100 𝜇M) exerted protection in both N27
cells and primary cell cultures, the concentration at 100 𝜇M
showed the best protective effect, whereas a higher dose
(>200𝜇M) was found to be toxic (data not shown). The 8 h
treatment of EGCG (100 𝜇M) on N27 cells reduced ROS
level (𝑝 < 0.01) compared with control (unpublished data),
indicating this level of EGCG did not have toxic effect. This
finding matches the bell-shaped pattern of EGCG, typical of
antioxidants, showing neuroprotection at low concentrations
and a prooxidant effect at higher concentrations [14, 15].
Various doses of EGCG (10–400 𝜇M) also were reported to
have a protective effect in other cell models [45, 46]. We used
100 𝜇MofEGCG,which is higher thanwhat onemight expect
under normal physiological conditions, because low doses
had been shown to be less effective.This higher dose may not
be achieved with a human diet, but it is possible with dietary
supplements.
Several proposed mechanisms may be attributed to the
neuroprotection capabilities of EGCG. First, it may regulate
iron-related proteins and maintain normal iron homeostasis
[47]. In this study, we showed that pretreatment by EGCG
counteracted the adverse effect of 6-OHDA on iron-related
proteins, leading to less intracellular iron accumulation. The
decreased iron accumulation with EGCG pretreatment was
supported by our 55Fe uptake data, which showed a 27%
decrease in iron burden compared with 6-OHDA treatment
alone. Second, EGCG may chelate iron, with the complex
not being taken up by the cell, reducing the iron-induced
reactive oxygen species generation, which we have shown in
another study (unpublished results). Third, EGCG also may
enhance the antioxidant system by upregulating antioxidant
enzymes [14, 48] and scavenging the free radicals directly.
The decreased oxidative stress may also affect the iron
homeostasis directly or indirectly. EGCG may also suppress
inflammatory activity, which may indirectly affect oxidative
stress and hepcidin and reduce the iron burden.
5. Conclusions
In conclusion, it was shown that EGCG has the potential
to prevent neurotoxicity. In this study, we did not see a
neurorescue effect of EGCG, because 6-OHDA might have
caused acute toxic effect in the in vitro condition. Future
studies are needed using a lower dosage in animal models.
Human studies on PD patients also would provide data to
study the effect of EGCG under physiological conditions.
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